BioCentury
ARTICLE | Company News

Curalogic inflammation, autoimmune news

December 8, 2008 8:00 AM UTC

Curalogic's board recommended the liquidation of the company's assets to its shareholders after it was unable to secure a partner for external development projects. In January, Curalogic reduced headcount and discontinued development of all its programs, including its Phase III vaccines for grass and ragweed allergies, to seek new development projects with external partners. ...